Understanding Esophageal Adenocarcinoma Through a Gene Signature
Author Information
Author(s): Fu Haijing, Liu Mengyan, Li Huiyu, Yu Li, Song Haizhu, Chu Xiaoyuan, Bao Wei
Primary Institution: Nanjing Medical University
Hypothesis
The study aims to identify PANoptosis-related genes associated with esophageal adenocarcinoma (EAC) and develop a prognostic model based on these genes.
Conclusion
The study presents a validated risk scoring model and prognostic nomogram that can predict patient outcomes and guide personalized treatments in esophageal adenocarcinoma.
Supporting Evidence
- The prognostic risk score model effectively predicts patient outcomes.
- The model outperforms traditional staging systems in predictive accuracy.
- Immune infiltration analysis revealed distinct immune profiles between risk groups.
- Drug sensitivity analysis indicated specific compounds that may be more effective in high-risk groups.
- MMP12 emerged as a key mediator in EAC progression.
Takeaway
Researchers looked at genes related to a type of cell death to help predict how patients with esophageal cancer will do, and they found a way to better guide treatments.
Methodology
The study used bioinformatics analysis of TCGA, GTEx, and GEO datasets to identify PANoptosis-related genes and developed a prognostic risk score model based on 8 significant genes.
Potential Biases
Technical and biological factors may affect gene expression measurements and their correlation with prognosis.
Limitations
The study's findings require further validation in larger, prospective, and multi-center studies due to potential inconsistencies in gene expression and prognostic trends.
Participant Demographics
The study included 720 samples, comprising 88 EAC samples from TCGA and 652 normal esophageal samples from GTEx.
Statistical Information
P-Value
p<0.05
Confidence Interval
95%CI=3.35~14.2
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website